Relevant myeloma and AL amyloidosis sessions at ASCO 2020

**CAR-T therapy**

- **BB2121 (IDE-CEL)**
  - Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results: [https://meetinglibrary.asco.org/record/186139/abstract](https://meetinglibrary.asco.org/record/186139/abstract)
  - KarMMa-RW: A study of real-world treatment patterns in heavily pre-treated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa: [https://meetinglibrary.asco.org/record/186190/abstract](https://meetinglibrary.asco.org/record/186190/abstract)

- **CARTITUDE**
  - Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma: [https://meetinglibrary.asco.org/record/186155/abstract](https://meetinglibrary.asco.org/record/186155/abstract)

- **ORVA-CEL**
  - Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011): [https://meetinglibrary.asco.org/record/186159/abstract](https://meetinglibrary.asco.org/record/186159/abstract)

**Novel agents**

- **SELINEXOR**
  - Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study: [https://meetinglibrary.asco.org/record/186143/abstract](https://meetinglibrary.asco.org/record/186143/abstract)

- **BELAMAF**
  - DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM): [https://meetinglibrary.asco.org/record/186921/abstract](https://meetinglibrary.asco.org/record/186921/abstract)
  - Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs): [https://meetinglibrary.asco.org/record/186180/abstract](https://meetinglibrary.asco.org/record/186180/abstract)
DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment: [https://meetinglibrary.asco.org/record/187591/abstract](https://meetinglibrary.asco.org/record/187591/abstract)


• **IXAZOMIB**
  
  Ixazomib Vs Placebo As Post-Induction Maintenance Therapy In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) not undergoing Autologous Stem Cell Transplant (ASCT): Phase 3 Tourmaline-MM4 Trial: [https://meetinglibrary.asco.org/record/186184/abstract](https://meetinglibrary.asco.org/record/186184/abstract)

• **CC-92480**
  
  First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): [https://meetinglibrary.asco.org/record/186136/abstract](https://meetinglibrary.asco.org/record/186136/abstract)

• **TECLISTAMAB**
  
  Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM): [https://meetinglibrary.asco.org/record/186864/abstract](https://meetinglibrary.asco.org/record/186864/abstract)

• **ISATUXIMAB**
  
AL amyloidosis

- Correlation between 24-hour proteinuria and spot urine albumin to creatinine ratio in systemic light chain amyloidosis: [https://meetinglibrary.asco.org/record/186178/abstract](https://meetinglibrary.asco.org/record/186178/abstract)
- Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light chain amyloidosis (AL): A study of 426 patients: [https://meetinglibrary.asco.org/record/186160/abstract](https://meetinglibrary.asco.org/record/186160/abstract)
- Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis: [https://meetinglibrary.asco.org/record/186142/abstract](https://meetinglibrary.asco.org/record/186142/abstract)
- Will adding alkylating agent to bortezomib improve survival of newly diagnosed AL amyloidosis patients? [https://meetinglibrary.asco.org/record/186152/abstract](https://meetinglibrary.asco.org/record/186152/abstract)